Xtandi Evrópusambandið - hollenska - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostaatnoplasma - endocriene therapie - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Yellox Evrópusambandið - hollenska - EMA (European Medicines Agency)

yellox

bausch + lomb ireland limited - bromfenac-natriumsesquihydraat - pain, postoperative; ophthalmologic surgical procedures - ophthalmologica - behandeling van postoperatieve oogontsteking na cataractextractie bij volwassenen.

Ganzed 0.3 mg/ml - 5 mg/ml oogdruppels opl. druppelfl. Belgía - hollenska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ganzed 0.3 mg/ml - 5 mg/ml oogdruppels opl. druppelfl.

horus pharma - timololmaleaat 6,83 mg/ml - eq. timolol 5 mg/ml; bimatoprost 0,3 mg/ml - oogdruppels, oplossing - 0,3 mg/ml - 5 mg/ml - bimatoprost 0.3 mg/ml; timololmaleaat 6.83 mg/ml - timolol, combinations

Levesialle 20 0,10 mg - 0,02 mg filmomh. tabl. Belgía - hollenska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

levesialle 20 0,10 mg - 0,02 mg filmomh. tabl.

exeltis germany gmbh - levonorgestrel 0,1 mg; ethinylestradiol 0,02 mg - filmomhulde tablet - 0,10 mg - 0,02 mg - levonorgestrel 0.1 mg; ethinylestradiol 0.02 mg - levonorgestrel and ethinylestradiol

Levesialle Continu 20 0.1 mg - 0.02 mg filmomh. tabl. Belgía - hollenska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

levesialle continu 20 0.1 mg - 0.02 mg filmomh. tabl.

exeltis germany gmbh - levonorgestrel 0,1 mg (roze tablet); ethinylestradiol 0,02 mg (roze tablet); placebo (witte tablet) - filmomhulde tablet - 0,10 mg - 0,02 mg - levonorgestrel 0.1 mg; ethinylestradiol 0.02 mg; placebo - levonorgestrel and ethinylestradiol

Lumivela Continu 20 0.15 mg - 0.02 mg filmomh. tabl. Belgía - hollenska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lumivela continu 20 0.15 mg - 0.02 mg filmomh. tabl.

exeltis germany gmbh - desogestrel 0,15 mg (witte tablet); ethinylestradiol 0,02 mg (witte tablet); placebo (groene tablet) - filmomhulde tablet - 0,150 mg - 0,020 mg - desogestrel 0.15 mg; ethinylestradiol 0.02 mg; placebo - desogestrel and ethinylestradiol

Lumivela Continu 30 0.15 mg - 0.03 mg filmomh. tabl. Belgía - hollenska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lumivela continu 30 0.15 mg - 0.03 mg filmomh. tabl.

exeltis germany gmbh - desogestrel 0,15 mg (witte tablet); ethinylestradiol 0,03 mg (witte tablet); placebo (groene tablet) - filmomhulde tablet - 0,150 mg - 0,030 mg - desogestrel 0.15 mg; ethinylestradiol 0.03 mg; placebo - desogestrel and ethinylestradiol

Filiop 40 µg/ml - 5 mg/ml oogdruppels opl. druppelfl. Belgía - hollenska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

filiop 40 µg/ml - 5 mg/ml oogdruppels opl. druppelfl.

horus pharma - timololmaleaat 6,83 mg - eq. timolol 5 mg/ml; travoprost 0,04 mg/ml - oogdruppels, oplossing - 40 µg/ml - 5 mg/ml - travoprost 0.04 mg/ml; timololmaleaat 6.83 mg - timolol, combinations

Adempas Evrópusambandið - hollenska - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hypertensie, pulmonair - antihypertensiva voor pulmonale arteriële hypertensie - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. de werkzaamheid is aangetoond in een pak van de bevolking inclusief de oorzaken van idiopathische of erfelijke pah of pah geassocieerd met bindweefselaandoeningen. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Advate Evrópusambandið - hollenska - EMA (European Medicines Agency)

advate

takeda manufacturing austria ag - octocog alfa - hemophilia a - antihemorragica - behandeling en profylaxe van bloedingen bij patiënten met hemofilie a (aangeboren factor-viii-tekort). advate bevat geen von willebrand factor in het farmacologisch effectieve hoeveelheden en is daarom niet vermeld in de von willebrand ziekte.